AGAlexander Tarek El Gammal

Alexander Tarek El Gammal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Tarek El Gammal has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients

    by Alexander Tarek El Gammal, Nathaniel Melling, Matthias Reeh, Florian Gebauer, Oliver Mann, Daniel Perez, Maximillian Bockhorn, Kai Bachmann, Jakob Robert Izbicki, Katharina Grupp


  • Open Access

    Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

    by Katharina Grupp, Bianca Hofmann, Asad Kutup, Kai Bachmann, Dean Bogoevski, Nathaniel Melling, Faik Guntac Uzunoglu, Alexander Tarek El Gammal, Christina Koop, Ronald Simon, et al.

    RBM3 expression has been suggested as prognostic marker in several cancer types. The purpose of this study was to assess the prevalence and clinical significance of altered RBM3 expression in esophageal cancer. RBM3 protein expression was measured by immunohistochemistry using tissue microarrays containing samples from 359 esophageal adenocarcinoma (EAC) and 254 esophageal squamous cell cancer (ESCC) patients with oncological follow-up data. While nuclear RBM3 expression was always high in benign esophageal epithelium, high RBM3 expression was only detectable in 66.4% of interpretable EACs and 59.3% of ESCCs. Decreased RBM3 expression was linked to a subset of EACs with advanced UICC stage and presence of distant metastasis (P = 0.0031 and P = 0.0024). In ESCC, decreased RBM3 expression was associated with advanced UICC stage, high tumor stage, and positive lymph node status (P = 0.0213, P = 0.0061, and P = 0.0192). However, RBM3 expression was largely unrelated to survival of patients with esophageal cancer (EAC: P = 0.212 and ESCC: P = 0.5992). In summary, the present study shows that decreased RBM3 expression is associated with unfavourable esophageal cancer phenotype, but not significantly linked to patient prognosis.


  • Inhibition of MALT1 protease with biperiden or mepazine: A new therapeutic treatment approach in pancreatic cancer.

    by Alexander T. El Gammal, Leonie Konczalla, Nadine Scholz, Clarissa Klemp, Johanna Lueddeke, Annika Wolski, Yao Dichao, Gerrit Wolters-Eisfeld, Baukloh Julia, Bianca T. Hofmann, et al.

    E14075 Background: Mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1) is a key mediator of NF-kB signaling and crucial for proliferation and anti-apoptosis in B-cell lymphomas. Mepazine (MEP) is a phenothiazine derivative and a potent MALT1 inhibitor. Biperiden (BIP) is a competitive receptor substrate of Phenotiazines. There is little data on the role of MALT1 in pancreatic ductal adenocarcinomas (PDAC). Methods: MALT1 expression was analyzed by IHC in 310 patients with PDAC. In silico docking was performed to determine favorable orientations and binding energies of MEP and BIP to the allosteric MALT1 binding pocket. Protein and mRNA expression of MALT1 were analyzed by Western blots and qRT-PCR. Five human PDAC cell lines were treated with different dosages of MEP and BIP. Proliferation rates were assessed by MTT and Ki67 assays. Apoptosis was determined by cleaved caspase 3 assays. MALT1 paracaspase activity assay was performed upon treatment with MEP or BIP. The effect of MEP and BIP on tumor size was evaluated by axenograft mouse model. A neurologic scoring was performed to asses adverse effects. Results: MALT1 is present in the majority of PDAC and absent in normal exocrine pancreatic tissue. BIP and MEP feature the same chemical structure activity relationship to the allosteric MALT1 binding-pocket. MALT1 is highly active in PDAC cells and can be inhibited by BIP or MEP leading to a significant reduction of proliferation and induction of apoptosis. Diminishing MALT1 activity prevents nuclear c-Rel translocation. PDAC tumor progression was significantly inhibited by BIP or MEP in vivo. Only mild neurologic adverse effects were determined. Conclusions: MEP and BIP are efficient inhibitors of MALT1 activity and PDAC tumor growth in vitro and in vivo. BIP or MEP treatment might be a promising new approach in pancreatic cancer therapy.


  • Open Access

    COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer

    by Bianca T. Hofmann, Laura Schlüter, Philip Lange, Baris Mercanoglu, Florian Ewald, Aljonna Fölster, Aeint-Steffen Picksak, Sönke Harder, Alexander T. El Gammal, Katharina Grupp, et al.

    Human pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies in the world and despite great efforts in research types of treatment remain limited. A frequently detected alteration in PDACs is a truncated O-linked N-acetylgalactosamine (GalNAc) glycosylation with expression of the Tn antigen. Changes in O-glycosylation affect posttranslationally modified O-GalNAc proteins resulting in profound cellular alterations. Tn antigen is a tumor associated glycan detected in 75-90 % of PDACs and up to 67 % in its precursor lesions. Since the role of Tn antigen expression in PDAC is insufficiently understood we analyzed the impact of COSMC mediated Tn antigen expression in two human PDAC cell lines on cellular oncogenic properties. Forced expression of Tn antigen on O-glycosylated proteins in pancreatic cancer cells was induced by lentiviral-mediated knockdown of the COSMC chaperone, which prevented O-glycan elongation beyond the initial GalNAcα1- residue on O-linked glycoproteins. Altered O-GalNAc glycosylation was analyzed in human pancreatic cancer cell lines Panc-1 and L3.6pl using Western and Far-Western blot as well as immunocytochemical techniques. To assess the biological implications of COSMC function on oncogenic properties, cell viability assays, scratch assays combined with live cell imaging, migration and apoptosis assays were performed. Lectin based glycoprotein enrichment with subsequent mass spectrometric analysis identified new cancer O-GalNAc modified proteins. Expression of Tn antigen bearing Nucleolin in patient derived PDAC tumor specimens was evaluated and correlated with clinicopathological data. Tn antigen expression was induced on various O-GalNAc glycoproteins in COSMC deficient cell lines compared to the control. Proliferation was reduced (p < 0.001) in COSMC knockdown cells, whereas migration was increased (p < 0.001) and apoptosis was decreased (p = 0.03), highlighting the importance of Tn antigen expression on metastatic and anti-apoptotic behavior of PDAC derived cells. Nucleolin was identified as O-GalNAc modified protein in COSMC deficient PDAC cell lines. Interestingly, immunohistochemical staining and co-localization studies of patient derived PDACs revealed poor survival for patients with strong co-localization of Tn antigen and Nucleolin (p = 0.037). This study substantiates the influence of altered O-glycan (Tn/STn) expression on oncogenic properties in pancreatic cancer and identifies O-GalNAc modified Nucleolin as novel prognostic marker.


  • Salvage Completion Pancreatectomies as Damage Control for Post‐pancreatic Surgery Complications: A Single‐Center Retrospective Analysis

    by Michael F. Nentwich, Alexander T. El Gammal, Torben Lemcke, Tarik Ghadban, Eugen Bellon, Nathaniel Melling, Kai Bachmann, Matthias Reeh, Faik G. Uzunoglu, Jakob R. Izbicki, et al.

    Background: Post‐pancreatic surgical morbidity is frequent but often manageable by less invasive means than re‐operation. Yet, some complications can become hazardous and life threatening. Herein, the results of a completion pancreatectomy (CP) to cope with severe post‐operative pancreatic fistulas (POPF) and bleeding complications after major pancreatic resections for suspected pancreatic malignancy are presented.Methods: CPs to treat severe post‐pancreatic index‐surgery complications between January 2002 and January 2012 were selected out of a prospective database. Indications for CP as well as perioperative data were prospectively collected and retrospectively assessed.Results: In 20 of 521 Kausch–Whipple Resections (3.8 %), a CP was necessary to treat post‐index surgery morbidity. Indications included insufficiency of the pancreaticojejunal anastomosis with resulting POPF in 14 (70.0 %) patients, severe bleeding complications in 6 (30.0 %) patients, and a severe portal vein thrombosis in 1 (5.0 %) patient. In 7 (35.0 %) of the 20 patients, the course was complicated by remnant pancreatitis. Eleven (55.0 %) of the 20 patients died during the hospital stay. Median time to re‐operation did not significantly differ between survivors and in‐hospital deaths (10.0 vs. 8.0 days; p = 0.732). Median hospital stay of the surviving patients was 31.0 (range 10–113) days. Re‐operations following CPs were necessary in 5 (55.6 %) of the 9 patients who survived and in 9 (81.8 %) out of 11 patients who died.Conclusions: Post‐pancreatic resection complications can become hazardous and result in severely ill patients requiring maximum therapy. CP in these cases has a high mortality but serves as an ultima ratio to cope with deleterious complications.